Last reviewed · How we verify
NCT06815965
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Phase 2 trial testing neflamapimod in Dementia With Lewy Bodies (DLB) in 26 participants. Completed in 25 March 2026.
11 March 2026
Quick facts
| Lead sponsor | EIP Pharma Inc |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 26 |
| Start date | 16 October 2024 |
| Primary completion | 11 March 2026 |
| Estimated completion | 25 March 2026 |
| Sites | 2 locations across France |
Drugs / interventions tested
- neflamapimod — full drug profile →
Conditions studied
- Dementia With Lewy Bodies (DLB) — all drugs for Dementia With Lewy Bodies (DLB) →
Sponsor
EIP Pharma Inc
Who can join
55 and older, any sex, with Dementia With Lewy Bodies (DLB). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical study is to evaluate the safety and tolerability (side effects) and pharmacokinetics (drug levels in the body) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer's disease therapy.
Ouro A, Ben-Dor GA, Debasa-Mouce M, Gulkarov S, et al · · 2026 · PMID 42039150 · DOI 10.3389/fcell.2026.1766762
Verify or expand the search:
- PubMed search for NCT06815965
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of neflamapimod
Trials testing the same drug.
- NCT03980938 — Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease · Phase 2 · terminated
- NCT03402659 — Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease · Phase 2 · completed
Other EIP Pharma Inc trials
Trials by the same sponsor.
- NCT06987643 — A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke · Phase 2 · recruiting
- NCT05869669 — RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies · Phase 2 · completed
- NCT04001517 — Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies · Phase 2 · completed
- NCT03980938 — Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease · Phase 2 · terminated
- NCT03402659 — Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06815965 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by EIP Pharma Inc
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06815965.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing